Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma (Q41346638)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.

24 February 2020

corrigendum / erratum

1 reference

10.1007/S11060-015-2024-6

Crossref

DOI

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1007/S11060-015-2024-6

author

William A Weiss

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Aleksandra K. Olow

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Theodore P Nicolaides

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

13

Sabine Mueller

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Tina Dasgupta

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Xiaodong Yang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Rintaro Hashizume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Maxwell Tom

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Yasuyuki Aoki

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Mitchel S Berger

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Lukas J A Stalpers

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Michael Prados

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

C David James

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Daphne A Haas-Kogan

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

1 reference

18 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuro-Oncology

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

126

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

385-393

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11060-015-1939-2

24 February 2020

exact match

0 references

cites work

Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Targeted therapy for BRAFV600E malignant astrocytoma.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

A reproducible brain tumour model established from human glioblastoma biopsies

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Constitutive activation of Raf-1 induces glioma formation in mice

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Clonogenic assay of cells in vitro.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

The concurrent chemoradiation paradigm--general principles

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Erlotinib: preclinical investigations

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

RAF antisense oligonucleotide as a tumor radiosensitizer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Severe radiotherapy-induced extracutaneous toxicity under vemurafenib

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Vemurafenib and radiosensitization.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Vemurafenib and radiation therapy in melanoma brain metastases

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Mutation analysis of B-RAF gene in human gliomas.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4907264

Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib

19 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26384810

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A Conserved RAS/Mitogen-Activated Protein Kinase Pathway Regulates DNA Damage–Induced Cell Death Postirradiation in Radelegans

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26384810

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-015-1939-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

24 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

PubMed publication ID

26384810

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26384810%20AND%20SRC:MED&resulttype=core&format=json